Results 11 to 20 of about 13,617 (225)
Pediatric Drugs, 2014 Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating immunoglobulin E (IgE) and expression of IgE high-affinity receptors on mast cells and basophils, interrupting the subsequent allergic inflammatory cascade.
LICARI, AMELIA +6 more
openaire +4 more sources
Roles of omalizumab in various allergic diseases
Allergology International, 2020 IgE and mast cells play a pivotal role in various allergic diseases, including asthma, allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved control of these allergic diseases and ...
Yoshimichi Okayama +2 more
exaly +3 more sources
Omalizumab: Clinical Use for the Management of Asthma [PDF]
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2012 Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β 2 agonist
Neil C. Thomson, Rekha Chaudhuri
doaj +2 more sources
Therapeutic Advances in Respiratory Disease, 2018 Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that ...
Corrado Pelaia +2 more
exaly +2 more sources
Indian Journal of Dermatology, 2015 Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.
Kiran Godse +4 more
openaire +4 more sources
A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma [PDF]
Frontiers in ImmunologyIntroductionPatients with severe asthma may benefit from targeted biological therapies. However, personalized therapy in children and adolescents with asthma, based on individual susceptibility to molecular mechanisms addressed by different biologicals ...
Boris Gole +19 more
doaj +2 more sources
OMALIZUMAB: EXPANDED OPPORTUNITIES FOR THE ATOPIC DISEASES TREATMENT
Педиатрическая фармакология, 2009 The review highlights experience and administration perspectives of the immunobiological medication Omalizumab in allergy. Omalizumab is the anti'IgE monoclonal antibody.
T.V. Kulichenko
doaj +4 more sources
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
Journal of Asthma and Allergy, 2009 Thomas SandströmDepartment of Respiratory Medicine and Allergy, University Hospital, Umeå, SwedenAbstract: Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma.
Thomas Sandström
doaj +1 more source
Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study
Frontiers in Immunology, 2022 BackgroundAllergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose.
Rui Tang +4 more
doaj +1 more source
Dermatology Practical & Conceptual, 2022 Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic ...
Irene Russo +3 more
doaj +1 more source